| Literature DB >> 29076303 |
Bobak Bahrami1,2, Thomas Hong2, Mark C Gilles1, Andrew Chang1,2.
Abstract
Diabetic retinopathy (DR) is a leading cause of vision impairment and blindness in the working-age population. The identification of vascular endothelial growth factor (VEGF) as a key mediator in the pathogenesis of DR has revolutionized the management of this vision-threatening disease. There is now strong evidence supporting intravitreal anti-VEGF therapy as first line in the management of sight-threatening diabetic macular edema (DME), along with a growing body of evidence to support the use of anti-VEGF drugs for proliferative DR. This review summarizes the role of VEGF in DR, the evidence for anti-VEGF therapy, safety considerations, and the future of anti-VEGF therapy for the management of DR. Copyright 2017 Asia-Pacific Academy of Ophthalmology.Entities:
Keywords: diabetic macular edema; diabetic retinopathy; vascular endothelial growth factor
Mesh：
Substances：
Year: 2017 PMID： 29076303 DOI： 10.22608/APO.2017350
Source DB: PubMed Journal: Asia Pac J Ophthalmol (Phila) ISSN： 2162-0989